This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Sidney Goldstein, MD

Arch Intern Med. 1979;139(10):1089-1090.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The β-adrenergic agent, propranolol hydrochloride, has become an important adjunct to the treatment of patients with coronary artery disease. Propranolol has become the foundation for the current medical treatment of angina pectoris based primarily upon the impressive symptom relief experienced following its administration. It is, however, unfortunate that there are little data relating to propranolol's effect on long-term morbidity and mortality in angina pectoris. As an extension of its presumed effectiveness in angina pectoris, propranolol is now being used in the routine treatment of patients who have experienced an acute myocardial infarction, regardless of the clinical course or symptom status. This therapy philosophy has been based largely on a number of studies performed in Europe using, for the most part, β-adrenergic blocking agents other than propranolol. Although these reports suggest that β-adrenergic blocking agents may improve survival following an acute myocardial infarction, it is far from a proven fact that . . . [Full Text PDF of this Article]

Author Affiliations
Division of Cardiovascular Medicine Henry Ford Hospital 2799 W Grand Blvd Detroit, MI 48202

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?